

Publication list of Division of Cardiology, Geneva University Hospital (January 2010-September 2011)

1. Delattre BM, Braunersreuther V, Gardier S, Hyacinthe JN, Crowe LA, Mach F, Vallée JP. Manganese kinetics demonstrated double contrast in acute but not in chronic infarction in a mouse model of myocardial occlusion reperfusion. *NMR Biomed*. In press 2011.
2. Arnaud C, Beguin PC, Lantuejoul S, Pepin JL, Guillermet C, Pelli G, Burger F, Buatois V, Ribuoit C, Baguet JP, Mach F, Levy P, Dematteis M. The Inflammatory Pre-Atherosclerotic Remodeling Induced by Intermittent Hypoxia is Attenuated by RANTES/CCL5 Inhibition. *Am J Respir Crit Care Med*. In press 2011.
3. Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE, Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P, Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldles M, Lawrence J, Harrington RA, Wallentin L; APPRAISE-2 Investigators. Apixaban with antiplatelet therapy after acute coronary syndrome. *N Engl J Med*. 365:699-708, 2011.
4. ACTIVE I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ. Irbesartan in patients with atrial fibrillation. *N Engl J Med*. 364:928-938, 2011.
5. Brochériou I, Maouche S, Durand H, Braunersreuther V, Le Naour G, Gratchev A, Koskas F, Mach F, Kzhyshkowska J, Ninio E. Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: implication in atherosclerosis. *Atherosclerosis*. 214:316-324, 2011.
6. Fokstuen S, Munoz A, Melacini P, Iliceto S, Perrot A, Ozcelik C, Jeanrenaud X, Rieubland C, Farr M, Faber L, Sigwart U, Mach F, Lerch R, Antonarakis SE, Blouin JL. Rapid detection of genetic variants in hypertrophic cardiomyopathy by custom DNA resequencing array in clinical practice. *J Med Genet*. In press 2011.
7. Ueland T, Dahl CP, Kjekshus J, Hulthe J, Böhm M, Mach F, Goudev A, Lindberg M, Wikstrand J, Aukrust P, Gullestad L. Osteoprotegerin Predicts Progression of Chronic Heart Failure: Results from CORONA. *Circ Heart Fail*. 4:145-152, 2011.
8. ACTIVE I Investigators, Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ. Irbesartan in patients with atrial fibrillation. *N Engl J Med*. 364:928-938, 2011.
9. Brochériou I, Maouche S, Durand H, Braunersreuther V, Le Naour G, Gratchev A, Koskas F, Mach F, Kzhyshkowska J, Ninio E. Antagonistic regulation of macrophage phenotype by M-CSF and GM-CSF: Implication in atherosclerosis. *Atherosclerosis*. 214:316-324, 2011.
10. Fontana P, Berdagué P, Castelli C, Nolli S, Barazer I, Fabbro-Peray P, Schved JF, Bounameaux H, Mach F, DE Moerloose P, Reny JL. Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. *J Thromb Haemost*. 2010 Dec;8(12):2614-23.

11. Mach F, Vogt P. [The rhythm of cardiology]. *Rev Med Suisse*. 2010 Jun 2;6(251):1107.
12. Vuilleumier N, Rossier MF, Pagano S, Python M, Charbonney E, Nkoulou R, James R, Reber G, Mach F, Roux-Lombard P. Anti-apolipoprotein A-1 IgG as an independent cardiovascular prognostic marker affecting basal heart rate in myocardial infarction. *Eur Heart J*. 2010 Apr;31(7):815-23.
13. Delattre BM, Braunersreuther V, Hyacinthe JN, Crowe LA, Mach F, Vallée JP. Myocardial infarction quantification with Manganese-Enhanced MRI (MEMRI) in mice using a 3T clinical scanner. *NMR Biomed*. 2010 Jun;23(5):503-13.
14. van der Harst P, Slart RH, Tio RA, Dunselman PH, Willemsen AT, van den Heuvel AF, Voors AA, van Veldhuisen DJ; CORONA Study Group. Effects of rosuvastatin on coronary flow reserve and metabolic mismatch in patients with heart failure (from the CORONA Study). *Am J Cardiol*. 2010 Feb 15;105(4):517-21.
15. Groscurin O, Plojoux J, Keller PF, Niquille M, N'koulou R, Mach F, Sarasin FP, Rutschmann OT. Prehospital emergency physician activation of interventional cardiology team reduces door-to-balloon time in ST-elevation myocardial infarction. *Swiss Med Wkly*. 2010 Apr 17;140(15-16):228-32.
16. Montet-Abou K, Daire JL, Hyacinthe JN, Jorge-Costa M, Grosdemange K, Mach F, Petri-Fink A, Hofmann H, Morel DR, Vallée JP, Montet X. In vivo labelling of resting monocytes in the reticuloendothelial system with fluorescent iron oxide nanoparticles prior to injury reveals that they are mobilized to infarcted myocardium. *Eur Heart J*. 2010 Jun;31(11):1410-20.
17. Lorgelly PK, Briggs AH, Wedel H, Dunselman P, Hjalmarson A, Kjekshus J, Waagstein F, Wikstrand J, János A, van Veldhuisen DJ, Barrios V, Fonseca C, McMurray JJ; CORONA Study Group. An economic evaluation of rosuvastatin treatment in systolic heart failure: evidence from the CORONA trial. *Eur J Heart Fail*. 2010 Jan;12(1):66-74.
18. Braunersreuther V, Pellioux C, Pelli G, Burger F, Steffens S, Montessuit C, Weber C, Proudfoot A, Mach F, Arnaud C. Chemokine CCL5/RANTES inhibition reduces myocardial reperfusion injury in atherosclerotic mice. *J Mol Cell Cardiol*. 2010 Apr;48(4):789-98.
19. Shah D. Filamentous thrombi during left-sided sheath-assisted catheter ablations. *Europace*. 2010 Dec;12(12):1657-8.
20. Park CI, Shah D. [Long-term pursuit of endurance sport: a new risk factor for atrial fibrillation?]. *Rev Med Suisse*. 2010 Jun 2;6(251):1122, 1124-6.
21. Shah DC, Lambert H, Nakagawa H, Langenkamp A, Aeby N, Leo G. Area under the real-time contact force curve (force-time integral) predicts radiofrequency lesion size in an in vitro contractile model. *J Cardiovasc Electrophysiol*. 2010 Sep;21(9):1038-43.
22. Shah D. Pulmonary vein isolation with the pulmonary vein ablation catheter (PVAC): is there a price to pay for a 'simpler', shorter procedure? *Europace*. 2010 Apr;12(4):455-7.
23. Patel S, Shah D, Chintala K, Karpawich PP. Atrial Baffle Problems Following the Mustard Operation in Children and Young Adults with Dextro-Transposition of the Great Arteries: The Need for Improved Clinical Detection in the Current Era. 2011 Jun 22.

24. Kuck KH, Reddy VY, Schmidt B, Natale A, Neuzil P, Saoudi N, Kautzner J, Herrera C, Hindricks G, Jaïs P, Nakagawa H, Lambert H, Shah DC. A novel radiofrequency ablation catheter using contact force sensing: Toccata study. *Heart Rhythm*. 2011 Aug 25. doi:10.1016/j.hrthm.2011.08.021.
25. Raviele A, Giada F, Bergfeldt L, Blanc JJ, Blomstrom-Lundqvist C, Mont L, Morgan JM, Raatikainen MJ, Steinbeck G, Viskin S, Kirchhof P, Braunschweig F, Borggrefe M, Hocini M, Della Bella P, Shah DC. Management of patients with palpitations: a position paper from the European Heart Rhythm Association. *Europace*. 2011 Jul; 13(7):920-34.
26. Burri H, Bennani I, Domenichini G, Ganière V, Sunthorn H, Stettler C, Gentil P, Shah D. Batrial pacing improves atrial haemodynamics and atrioventricular timing compared with pacing from the right atrial appendage. *Europace*. 2011 Sep;13(9):1262-7
27. Shah D. Twelve-lead ECG interpretation in a patient with presumed left atrial flutter following AF ablation. *J Cardiovasc Electrophysiol*. 2011 May;22(5):613-7
28. Shah D. A critical appraisal of cardiac ablation technology for catheter-based treatment of atrial fibrillation. *Expert Rev Med Devices*. 2011 Jan;8(1):49-55.
29. Shah D. Is gold cooler than platinum-iridium? *Europace*. 2011 Jan;13(1):9-10.
30. Shah D, Lambert H, Langenkamp A, Vanenkov Y, Leo G, Gentil-Baron P, Walpoth B. Catheter tip force required for mechanical perforation of porcine cardiac chambers. *Europace*. 2011 Feb; 13(2):277-83.
31. Shah D. The role of MRI-detected left atrial delayed enhancement in selecting the right patient and choosing the optimal strategy for catheter ablation of atrial fibrillation. *J Cardiovasc Electrophysiol*. 2011 Jan;22(1):23-4
32. Burri H, Park CI, Zimmermann M, Gentil-Baron P, Stettler C, Sunthorn H, Domenichini G, Shah D. Utility of the surface electrocardiogram for confirming right ventricular septal pacing: validation using electroanatomical mapping. *Europace*. 2011 Jan; 13(1):82-6.
33. Shah D. Filamentous thrombi during left-sided sheath-assisted catheter ablations. *Europace*. 2010 Dec; 12(12):1657-8.
34. Park CI, Shah D. [Long-term pursuit of endurance sport: a new risk factor for atrial fibrillation?]. *Rev Med Suisse*. 2010 Jun 2; 6(251):1122, 1124-6.
35. Burri H, Domenichini G, Sunthorn H, Fleury E, Stettler C, Foulkes I, Shah D. Right ventricular systolic function and cardiac resynchronization therapy. *Europace*. 2010 Mar; 12(3):389-94.
36. Raeis V, Philip-Couderc P, Roatti A, Habre W, Sierra J, Kalangos A, Beghetti M, Baertschi AJ. Central venous hypoxemia is a determinant of human atrial ATP-sensitive potassium channel expression: evidence for a novel hypoxia-inducible factor 1alpha-Forkhead box class O signaling pathway. *Hypertension*. 2010 May;55(5):1186-92.
37. Fraisse A, Jais X, Schleich JM, di Filippo S, Maragnès P, Beghetti M, Gressin V, Voisin M, Dauphin C, Clerson P, Godart F, Bonnet D. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. *Arch Cardiovasc Dis*. 2010 Feb; 103(2):66-74.

38. Tissières P, Myers P, Beghetti M, Berner M, Rimensberger PC. Surfactant use based on the oxygenation response to lung recruitment during HFOV in VLBW infants. *Intensive Care Med.* 2010 Jul;36(7):1164-70.
39. von Ungern-Sternberg BS, Habre W, Regli A, Pache JC, Fontao F, Janosi TZ, Beghetti M, Peták F. Precapillary pulmonary hypertension leads to reversible bronchial hyperreactivity in rats. *Exp Lung Res.* 2010 Apr;36(3):129-39.
40. Haworth SG, Beghetti M. Assessment of endpoints in the pediatric population: congenital heart disease and idiopathic pulmonary arterial hypertension. *Curr Opin Pulm Med.* 2010 May;16 Suppl 1:S35-41.
41. Maggio AB, Hofer MF, Martin XE, Marchand LM, Beghetti M, Farpour-Lambert NJ. Reduced physical activity level and cardiorespiratory fitness in children with chronic diseases. *Eur J Pediatr.* 2010 Oct; 169(10):1187-93.
42. Beghetti M. Fontan and the pulmonary circulation: a potential role for new pulmonary hypertension therapies. *Heart.* 2010 Jun;96(12):911-6.
43. Tissot C, Ivy DD, Beghetti M. Medical therapy for pediatric pulmonary arterial hypertension. *J Pediatr.* 2010 Oct;157(4):528-32.
44. Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, Gatzoulis MA, Gohlke-Baerwolf C, Kaemmerer H, Kilner P, Meijboom F, Mulder BJ, Oechslin E, Oliver JM, Serraf A, Szatmari A, Thaulow E, Vouhe PR, Walma E, Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P, McDonagh T, Swan L, Andreotti F, Beghetti M, Borggrefe M, Bozio A, Brecker S, Budts W, Hess J, Hirsch R, Jondeau G, Kokkonen J, Kozelj M, Kucukoglu S, Laan M, Lionis C, Metreveli I, Moons P, Pieper PG, Pilosoff V, Popelova J, Price S, Roos-Hesselink J, Uva MS, Tornos P, Trindade PT, Ukkonen H, Walker H, Webb GD, Westby J; Task Force on the Management of Grown-up Congenital Heart Disease of the European Society of Cardiology (ESC). ESC Guidelines for the management of grown-up congenital heart disease (new version 2010). *Eur Heart J.* 2010 Dec;31(23):2915-57.
45. Trigona B, Aggoun Y, Maggio A, Martin XE, Marchand LM, Beghetti M, Farpour-Lambert NJ. Preclinical noninvasive markers of atherosclerosis in children and adolescents with type 1 diabetes are influenced by physical activity. *J Pediatr.* 2010 Oct;157(4):533-9.
46. Maggio AB, Ferrari S, Kraenzlin M, Marchand LM, Schwitzgebel V, Beghetti M, Rizzoli R, Farpour-Lambert NJ. Decreased bone turnover in children and adolescents with well controlled type 1 diabetes. *J Pediatr Endocrinol Metab.* 2010 Jul;23(7):697-707.
47. Christenson JT, Sierra J, Colina Manzano NE, Jolou J, Beghetti M, Kalangos A. Homografts and xenografts for right ventricular outflow tract reconstruction: long-term results. *Ann Thorac Surg.* 2010 Oct;90(4):1287-93.
48. Beghetti M, Tissot C. Pulmonary hypertension in congenital shunts. *Rev Esp Cardiol.* 2010 Oct;63(10):1179-93.

49. Schulze-Neick I, Beghetti M. Issues related to the management and therapy of paediatric pulmonary hypertension. *Eur Respir Rev.* 2010 Dec 1;19(118):331-9.
50. Berger RM, Beghetti M, Galiè N, Gatzoulis MA, Granton J, Lauer A, Chiossi E, Landzberg M. Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: a subgroup analysis. *Int J Cardiol.* 2010 Oct 29; 144(3):373-8.
51. Maggio AB, Aggoun Y, Martin XE, Marchand LM, Beghetti M, Farpour-Lambert NJ. Long-term follow-up of cardiovascular risk factors after exercise training in obese children. *Int J Pediatr Obes.* 2011 Jun;6(2-2):e603-10.
52. Ishida H, Kogaki S, Ichimori H, Narita J, Nawa N, Ueno T, Takahashi K, Kayatani F, Kishimoto H, Nakayama M, Sawa Y, Beghetti M, Ozono K. Overexpression of endothelin-1 and endothelin receptors in the pulmonary arteries of failed Fontan patients. *Int J Cardiol.* 2011. doi:10.1016/j.ijcard.2011.02.021.
53. Barst RJ, Ertel SI, Beghetti M, Ivy DD. Pulmonary arterial hypertension: a comparison between children and adults. *Eur Respir J.* 2011 Mar;37(3):665-77.
54. Habre W, Albu G, Janosi TZ, Fontao F, von Ungern-Sternberg BS, Beghetti M, Petak F. Prevention of bronchial hyperreactivity in a rat model of precapillary pulmonary hypertension. *Respir Res.* 2011 Apr 27;12:58.
55. Myers P, Beghetti M, Cikirikcioglu M, Sierra J, Aggoun Y, Touati R, Kalangos A. Novel approach to mitral valve repair in childhood dilated cardiomyopathy. *Minerva Chir.* 2011 Apr;66(2):119-21.
56. da Cruz E, Lechner E, Stiller B, Munoz R, Beghetti M, Fakler U, Haas N. Recommendations from the Association for European Paediatric Cardiology for training in paediatric cardiac intensive care. *Cardiol Young.* 2011 Aug;21(4):480-4.
57. Baumgartner C, Roffi M, Perrier A, Carballo S. [Stable and asymptomatic coronary heart disease: a new paradigm]. *Rev Med Suisse.* 2010 Oct 20;6(267):1951-4, 1956.
58. Thalhammer C, Joerg GR, Roffi M, Husmann M, Pfammatter T, Amann-Vesti BR. Endovascular treatment of Angio-Seal-related limb ischemia--primary results and long-term follow-up. *Catheter Cardiovasc Interv.* 2010 May 1;75(6):823-7.
59. Roffi M, Sievert H, Gray WA, White CJ, Torsello G, Cao P, Reimers B, Mathias K, Setacci C, Schönholz C, Clair DG, Schillinger M, Grunwald I, Bosiers M, Abou-Chebl A, Moussa ID, Mudra H, Iyer SS, Scheinert D, Yadav JS, van Sambeek MR, Holmes DR, Cremonesi A. Carotid artery stenting versus surgery: adequate comparisons? *Lancet Neurol.* 2010 Apr; 9(4):339-41; author reply 341-2.
60. Fontana P, Bonvini RF, Roffi M, Boehlen F, Reber G, de Moerloose P, Reny JL. [Evaluating the biological efficacy of clopidogrel: genotype or phenotype?]. *Rev Med Suisse.* 2010 Feb 10;6(235):302-5.
61. Roffi M. Peripheral arterial disease. Current evidence for carotid endarterectomy and carotid artery stenting. *Heart.* 2010 Apr; 96(8):636-42.
62. Roffi M, Narata AP, Pereira VM. [AVC: surgery or carotid stents?]. *Rev Med Suisse.* 2010 Mar 17;6(240):596-7; author reply 597.

63. Wyss CA, Neidhart M, Altwegg L, Spanaus KS, Yonekawa K, Wischnewsky MB, Corti R, Kucher N, Roffi M, Eberli FR, Amann-Vesti B, Gay S, von Eckardstein A, Lüscher TF, Maier W. Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. *Eur Heart J*. 2010 Jun;31(12):1457-69.
64. Kummer O, Roffi M, Marti G, Mach F. [Clopidogrel and its salts: any clinical implication?]. *Rev Med Suisse*. 2010 Jun 2; 6(251):1127-8, 1130-2.
65. Di Mario C, Boehm M, Dudek D, Eeckhout E, Roffi M. The Show is Over: time to start preparing the new one. *EuroIntervention*. 2010 Nov; 6(5):555-9.
66. Roffi M. Is there a role for revascularisation in asymptomatic carotid stenosis? Yes. *BMJ*. 2010 Sep 15; 341:c4898.
67. Roffi M, Cremonesi A. Carotid artery stenting versus endarterectomy for carotid stenosis. *Lancet*. 2010 Jul 31; 376(9738):327; author reply 327-8.
68. Roffi M, Angiolillo DJ, Kappetein AP. Current concepts on coronary revascularization in diabetic patients. *Eur Heart J*. 2011 Sep 4.
69. Authors/Task Force Members, Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS, Storey RF, Wijns W, Zahger D; ESC Committee for Practice Guidelines, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Windecker S, Achenbach S, Badimon L, Bertrand M, Bøtker HE, Collet JP, Crea F, Danchin N, Falk E, Goudevenos J, Gulba D, Hambrecht R, Herrmann J, Kastrati A, Kjeldsen K, Kristensen SD, Lancellotti P, Mehilli J, Merkely B, Montalescot G, Neumann FJ, Neyses L, Perk J, Roffi M, Romeo F, Ruda M, Swahn E, Valgimigli M, Vrints CJ, Widimsky P. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). *Eur Heart J*. 2011 Aug 26.
70. Endorsed by: the European Stroke Organisation (ESO); Authors/Task Force Members, Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clément D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kownator S, Minar E, Ostergren J, Poldermans D, Riambau V, Roffi M, Röther J, Sievert H, van Sambeek M, Zeller T; ESC Committee for Practice Guidelines (CPG), Bax J, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu B, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A, Windecker S; Document Reviewers, Kolh P, Torbicki A, Agewall S, Blinc A, Bulvas M, Cosentino F, De Backer T, Gottsäter A, Gulba D, Guzik TJ, Jönsson B, Késmárky G, Kitsiou A, Kuczmik W, Larsen ML, Madaric J, Mas JL, McMurray JJ, Micari A, Mosseri M, Müller C, Naylor R, Norrving B, Oto O, Pasierski T, Plouin PF, Ribichini F, Ricco JB, Ruilope L, Schmid JP, Schwehr U, Sol BG, Sprynger M, Tiefenbacher C, Tsioufis C, Van Damme H. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of

extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries *
The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the
European Society of Cardiology (ESC). *Eur Heart J*. 2011 Aug 26.

71. Bonvini RF, Rastan A, Sixt S, Noory E, Schwarz T, Frank U, Roffi M, Dorsaz PA, Schwarzwälder U, Bürgelin K, Macharzina R, Zeller T. Endovascular treatment of common femoral artery disease medium-term outcomes of 360 consecutive procedures. *J Am Coll Cardiol*. 2011 Aug 16; 58(8):792-8.
72. Testuz A, Roffi M, Bonvini RF. Coronary to pulmonary artery fistulas: an incidental finding with challenging therapeutic options. *J Invasive Cardiol*. 2011 Jul; 23(7):E177-80.
73. Noble S, Roffi M. [Transcatheter aortic valve implantations in 2011: the interventional cardiologist]. *Rev Med Suisse*. 2011 Jun 1; 7(297):1207-11.
74. Carballo S, Carballo D, Keller PF, Roffi M. [Specificities of diabetes in acute coronary syndromes]. *Rev Med Suisse*. 2011 Jun 1; 7(297):1200-2, 1204-6.
75. Grisel P, Roffi M, Müller H, Keller PF. [Mechanical complications of myocardial infarction]. *Rev Med Suisse*. 2011 Jun 1; 7(297):1189-92.
76. Angiolillo DJ, Roffi M, Fernandez-Ortiz A. Tackling the thrombotic burden in patients with acute coronary syndrome and diabetes mellitus. *Expert Rev Cardiovasc Ther*. 2011 Jun; 9(6):697-710.
77. Di Mario C, Roffi M. Peripheral interventions: how long will they remain a missed opportunity? *EuroIntervention*. 2011 Jun; 7(2):177-81.
78. Noble S, Roffi M, Burri H. Use of an Explanted Pacemaker Connected to a Regular Screw-in Lead for Temporary Pacing. *Rev Esp Cardiol*. 2011 May 20.
79. Noble S, Vilarino R, Muller H, Sunthorn H, Roffi M. Fatal coronary sinus and aortic erosions following percutaneous transvenous mitral annuloplasty device. *EuroIntervention*. 2011 May; 7(1):148-50.
80. Cherian S, Roffi M, Kalangos A, Cikirikcioglu M. Rapid progression of left main coronary disease causing acute coronary syndrome. *Ann Thorac Surg*. 2011 May; 91(5):1625.
81. Cikirikcioglu M, Cherian S, Lerch R, Licker MJ, Roffi M, Bonvini RF, Kalangos A. Late tamponade secondary to aortic root perforation by BioSTAR septal closure device. *Ann Thorac Surg*. 2011 Feb; 91(2):604-6.
82. Grunwald IQ, Wakhloo AK, Walter S, Molyneux AJ, Byrne JV, Nagel S, Kühn AL, Papadakis M, Fassbender K, Balami JS, Roffi M, Sievert H, Buchan A. Endovascular stroke treatment today. *AJNR Am J Neuroradiol*. 2011 Feb; 32(2):238-43.
83. Bonvini RF, Roffi M, Righini M. [New techniques for the endovascular treatment of peripheral arterial disease]. *J Mal Vasc*. 2011 Feb; 36(1):16-23.
84. Baumgartner C, Roffi M, Perrier A, Carballo S. [Stable and asymptomatic coronary heart disease: a new paradigm]. *Rev Med Suisse*. 2010 Oct 20; 6(267):1951-4, 1956.

85. Reny JL, Bonvini RF, Bonvini JM, Roffi M, Fontana P. Poor Responsiveness to Antiplatelet Drugs in Acute Coronary Syndromes: Clinical Relevance and Management. *Cardiovasc Ther*. 2010 Nov 14. doi: 10.1111/j.1755-5922.2010.00248.x.
86. Noble S, Ibrahim R, Basmadjian A, Müller H, Lerch R, Roffi M. [Paravalvular leak following surgical valve replacement: is there a role for percutaneous paravalvular leak reduction?]. *Rev Med Suisse*. 2010 Jun 2;6(251):1154-8.
87. Wyss CA, Neidhart M, Altwegg L, Spanaus KS, Yonekawa K, Wischnewsky MB, Corti R, Kucher N, Roffi M, Eberli FR, Amann-Vesti B, Gay S, von Eckardstein A, Lüscher TF, Maier W. Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. *Eur Heart J*. 2010 Jun; 31(12):1457-69.
88. Keller PF, Carballo D, Roffi M. Diabetes and acute coronary syndrome. *Minerva Med*. 2010 Apr;101(2):81-104.
89. CURRENT-OASIS 7 Investigators, Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, Granger CB, Jolly S, Joyner CD, Rupprecht HJ, Widimsky P, Afzal R, Pogue J, Yusuf S. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. *N Engl J Med*. 2010 Sep 2;363(10):930-42.
90. Radovanovic D, Urban P, Simon R, Schmidli M, Maggiorini M, Rickli H, Stauffer JC, Seifert B, Gutzwiller F, Erne P; AMIS Plus Investigators. Outcome of patients with acute coronary syndrome in hospitals of different sizes. A report from the AMIS Plus Registry. *Swiss Med Wkly*. 2010 May 29;140(21-22):314-22.
91. Groscurin O, Plojoux J, Keller PF, Niquille M, N'koulou R, Mach F, Sarasin FP, Rutschmann OT. Prehospital emergency physician activation of interventional cardiology team reduces door-to-balloon time in ST-elevation myocardial infarction. *Swiss Med Wkly*. 2010 Apr 17;140(15-16):228-32.
92. Cuculi F, Radovanovic D, Pedrazzini G, Regli M, Urban P, Stauffer JC, Erne P; AMIS Plus Investigators. Is pretreatment with Beta-blockers beneficial in patients with acute coronary syndrome? *Cardiology*. 2010;115(2):91-7.
93. Müller H, Keller PF, Lerch R. "Pinball" in the left atrium. *Echocardiography*. 2010 Mar; 27(3):354-5.
94. Carballo D, Auer R, Carballo S, Windecker S, Matter C, Luscher T, Vogt P, Perneger T, Mach F, Rodondi N, Keller PF; SPUM-ACS. [A Swiss multicentric project to improve the prevention of cardiovascular event recurrence after acute coronary syndromes]. *Rev Med Suisse*. 2010 Mar 10; 6(239):518, 520-2, 524.
95. Meyer P, Kayser B, Kossovsky MP, Sigaud P, Carballo D, Keller PF, Martin XE, Farpour-Lambert N, Pichard C, Mach F. Stairs instead of elevators at workplace: cardioprotective effects of a pragmatic intervention. *Eur J Cardiovasc Prev Rehabil*. 2010 Oct; 17(5):569-75.
96. Schoenenberger AW, Radovanovic D, Stauffer JC, Windecker S, Urban P, Niedermaier G, Keller PF, Gutzwiller F, Erne P; AMIS Plus Investigators. Acute coronary syndromes in young patients: presentation, treatment and outcome. *Int J Cardiol*. 2011 May 5; 148(3):300-4.

97. Cuculi F, Radovanovic D, Pedrazzini G, Regli M, Urban P, Stauffer JC, Erne P; AMIS Plus Investigators. Is pretreatment with Beta-blockers beneficial in patients with acute coronary syndrome? *Cardiology*. 2010; 115(2):91-7.
98. Burri H, Domenichini G, Sunthorn H, Fleury E, Stettler C, Foulkes I, Shah D. Right ventricular systolic function and cardiac resynchronization therapy. *Europace*. 2010 Mar;12(3):389-94.
99. Burri H. Paced QRS morphology for confirming septal pacemaker lead implantation: correction of a misconception. *Europace*. 2010 Dec;12(12):1660-1.
100. Burri H, Quesada A, Ricci RP, Boriani G, Davinelli M, Favale S, Da Costa A, Kautzner J, Moser R, Navarro X, Santini M. The MOnitoring Resynchronization dEVICES and CARdiac patiEnts (MORE-CARE) study: rationale and design. *Am Heart J*. 2010 Jul;160(1):42-8.
101. Ruitter JH, Mulder E, Schuchert A, Burri H, Stühlinger MC, Hartikainen J, Sermasi S, Vlasínová J, Mairesse GH, Bub E, Lewalter T; T-STAR Study Group. The feasibility of fully automated pacemaker advise in treating atrial tachyarrhythmias. *Pacing Clin Electrophysiol*. 2010 May;33(5):605-14.
102. Conti L, Tran N, Burri H, Zimmermann M. Failure of an implantable cardioverter defibrillator to terminate ventricular tachycardia: why? *Pacing Clin Electrophysiol*. 2010 Feb;33(2):228-30.
103. Ganiere V, Cassagneau R, Burri H, Defaye P. Inappropriate mode switch consecutive to P-wave double counting. *Europace*. 2011 Jun 28.
104. Burri H. Cardiac resynchronization therapy for mild-to-moderate heart failure. *Expert Rev Med Devices*. 2011 May; 8(3):313-7.
105. Boriani G, Burri H, Mantovani LG, Maniadakis N, Leyva F, Kautzner J, Lubinski A, Braunschweig F, Jung W, Lozano IF, Fattore G. Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario. *Europace*. 2011 May;13 Suppl 2:ii59-65.
106. Burri H, Heidbüchel H, Jung W, Brugada P. Remote monitoring: a cost or an investment? *Europace*. 2011 May;13 Suppl 2:ii44-8.
107. Ganière V, Burri H. [Remote management of pacemakers and implantable cardioverter defibrillators: an application of telemedicine]. *Rev Med Suisse*. 2011 Mar 9;7(285):548-50, 552-3.
108. Burri H. Paced QRS morphology for confirming septal pacemaker lead implantation: correction of a misconception. *Europace*. 2010 Dec; 12(12):1660-1.
109. Ruitter JH, Mulder E, Schuchert A, Burri H, Stühlinger MC, Hartikainen J, Sermasi S, Vlasínová J, Mairesse GH, Bub E, Lewalter T; T-STAR Study Group. The feasibility of fully automated pacemaker advise in treating atrial tachyarrhythmias. *Pacing Clin Electrophysiol*. 2010 May; 33(5):605-14.
110. Conti L, Tran N, Burri H, Zimmermann M. Failure of an implantable cardioverter defibrillator to terminate ventricular tachycardia: why? *Pacing Clin Electrophysiol*. 2010 Feb; 33(2):228-30.

111. Müller H, Frangos C, Fleury E, Righetti A, Lerch R, Burri H. Measurement of left ventricular ejection fraction by real time 3D echocardiography in patients with severe systolic dysfunction: comparison with radionuclide angiography. *Echocardiography*. 2010 Jan; 27(1):58-63.
112. Noble S, Sunthorn H, Prat-González S. [Apical aneurysm in a full-contact fighter]. *Rev Esp Cardiol*. 2011 Jun; 64(6):535-6.
113. Edvardsson N, Frykman V, van Mechelen R, Mitro P, Mohii-Oskarsson A, Pasquié JL, Ramanna H, Schwertfeger F, Ventura R, Voulgaraki D, Garutti C, Stolt P, Linker NJ; PICTURE Study Investigators. Use of an implantable loop recorder to increase the diagnostic yield in unexplained syncope: results from the PICTURE registry. *Europace*. 2011 Feb; 13(2):262-9.
114. Vincenti G, Quercioli A, Zaïdi H, Nkoulou R, Dewarrat S, Rager O, Ambrosio G, Seimbille Y, Mach F, Ratib O, Schindler TH. Combined evaluation of myocardial perfusion and coronary morphology in the identification of subclinical CAD. Radiation exposure of 13N-ammonia PET/CT. *Nuklearmedizin*. 2010;49(5):173-82.
115. Valenta I, Quercioli A, Vincenti G, Nkoulou R, Dewarrat S, Rager O, Zaidi H, Seimbille Y, Mach F, Ratib O, Schindler TH. Structural epicardial disease and microvascular function are determinants of an abnormal longitudinal myocardial blood flow difference in cardiovascular risk individuals as determined with PET/CT. *J Nucl Cardiol*. 2010 Dec;17(6):1023-33
116. Ghafarian P, Aghamiri SM, Ay MR, Fallahi B, Rahmim A, Schindler TH, Ratib O, Zaidi H. Coronary calcium score scan-based attenuation correction in cardiovascular PET imaging. *Nucl Med Commun*. 2010 Sep;31(9):780-7.
117. Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. *JACC Cardiovasc Imaging*. 2010 Jun;3(6):623-40.
118. Schindler TH. Adapting the contrast material protocol to the body surface area for an optimized low-dose CT coronary angiography with prospective ECG-triggering: a new evolving concept? *Int J Cardiovasc Imaging*. 2010 Jun;26(5):599-600.
119. Cardiovascular Council Board of Directors. Cardiovascular nuclear imaging: balancing proven clinical value and potential radiation risk. *J Nucl Med*. 2011 Jul; 52(7):1162-4.
120. Valenta I, Landmesser U, Schindler TH. Vascular function of the peripheral and coronary circulation: worthwhile to assess their relation? *J Nucl Cardiol*. 2011 Apr;18(2):201-3.
121. Quercioli A, Pataky Z, Vincenti G, Makoundou V, Di Marzo V, Montecucco F, Carballo S, Thomas A, Staub C, Steffens S, Seimbille Y, Golay A, Ratib O, Harsch E, Mach F, Schindler TH. Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. *Eur Heart J*. 2011 Jun;32(11):1369-78.
122. Schindler TH, Quercioli A. Left ventricular dyssynchrony assessment by phase analysis from gated myocardial perfusion SPECT: moving beyond conventional criteria. *Heart*. 2011 Jan;97(1):4-5.

123. Ghafarian P, Aghamiri SM, Ay MR, Rahmim A, Schindler TH, Ratib O, Zaidi H. Is metal artefact reduction mandatory in cardiac PET/CT imaging in the presence of pacemaker and implantable cardioverter defibrillator leads? *Eur J Nucl Med Mol Imaging*. 2011 Feb;38(2):252-62.
124. Vincenti G, Quercioli A, Zaïdi H, Nkoulou R, Dewarrat S, Rager O, Ambrosio G, Seimbille Y, Mach F, Ratib O, Schindler TH. Combined evaluation of myocardial perfusion and coronary morphology in the identification of subclinical CAD. Radiation exposure of 13N-ammonia PET/CT. *Nuklearmedizin*. 2010;49(5):173-82.
125. Valenta I, Quercioli A, Vincenti G, Nkoulou R, Dewarrat S, Rager O, Zaidi H, Seimbille Y, Mach F, Ratib O, Schindler TH. Structural epicardial disease and microvascular function are determinants of an abnormal longitudinal myocardial blood flow difference in cardiovascular risk individuals as determined with PET/CT. *J Nucl Cardiol*. 2010 Dec;17(6):1023-33.
126. Ghafarian P, Aghamiri SM, Ay MR, Fallahi B, Rahmim A, Schindler TH, Ratib O, Zaidi H. Coronary calcium score scan-based attenuation correction in cardiovascular PET imaging. *Nucl Med Commun*. 2010 Sep;31(9):780-7.
127. Schindler TH, Schelbert HR, Quercioli A, Dilsizian V. Cardiac PET imaging for the detection and monitoring of coronary artery disease and microvascular health. *JACC Cardiovasc Imaging*. 2010 Jun;3(6):623-40. Schindler TH. Adapting the contrast material protocol to the body surface area for an optimized low-dose CT coronary angiography with prospective ECG-triggering: a new evolving concept? *Int J Cardiovasc Imaging*. 2010 Jun;26(5):599-600.
128. Cardiovascular Council Board of Directors. Cardiovascular nuclear imaging: balancing proven clinical value and potential radiation risk. *Nucl Med*. 2011 Jul;52(7):1162-4.
129. Müller H, Burri H, Gentil P, Lerch R, Shah D. Measurement of left atrial volume in patients undergoing ablation for atrial fibrillation: comparison of angiography and electro-anatomic (CARTO) mapping with real-time three-dimensional echocardiography. *Europace*. 2010 Jun;12(6):792-7.
130. Müller H, Frangos C, Fleury E, Righetti A, Lerch R, Burri H. Measurement of left ventricular ejection fraction by real time 3D echocardiography in patients with severe systolic dysfunction: comparison with radionuclide angiography. *Echocardiography*. 2010 Jan;27(1):58-63.
131. Müller H, Kalangos A, Fassa AA, Lerch R. Isolated cleft mitral valve with posterior and anterior clefts: a rare cause of congenital valve regurgitation. *Echocardiography*. 2010 May;27(5):E50-2.
132. Müller H, Willi JP, Lerch R. Non-infectious large vessel vasculitis of the aorta: diagnosis by echocardiography and cardiac positron emission tomography-computed tomography. *Eur Heart J*. 2010 Sep;31(18):2245.
133. Pektok E, Sierra J, Cikirikcioglu M, Müller H, Myers PO, Kalangos A. Midterm results of valve repair with a biodegradable annuloplasty ring for acute endocarditis. *Ann Thorac Surg*. 2010 Apr;89(4):1180-5.

134. Müller H, Cikirikcioglu M, Lerch R. Isolated posterior mitral valve cleft: diagnosis by real-time three-dimensional transoesophageal echocardiography. *Eur J Echocardiogr.* 2010 Aug;11(7):E29.
135. Peyrou J, Lerch R, Müller H. Silent embolization of a large left ventricular thrombus. *Arch Cardiovasc Dis.* 2010 Jan;103(1):59-60.
136. Mégevand P, Vincenti GM, Carballo D, Bally J, Pereira VM, Lovblad KO, Poggia D, Müller H, Sekoranja L. A palpable source of stroke. *Circulation.* 2011 Aug 30;124(9):e232-3.
137. Müller H, Park CI, Lerch R. Dyspnoea and blood pressure fall at exercise: usefulness of exercise echocardiography. *Arch Cardiovasc Dis.* 2011 Feb;104(2):140-1.
138. Bonvini RF, Roffi M. Tools & techniques: aortoiliac and common femoral endovascular interventions. *EuroIntervention.* 2010 Jun;6(2):288-9.
139. Bonvini RF, Roffi M. [Endovascular treatment of below the knee arteries in critical limb ischemia]. *Rev Med Suisse.* 2010 Jun 2;6(251):1146-8, 1150-3.
140. Bonvini RF, Righini M, Roffi M. Angiojet rheolytic thrombectomy in massive pulmonary embolism: locally efficacious but systemically deleterious? *J Vasc Interv Radiol.* 2010 Nov;21(11):1774-6; author reply 1776-7.
141. Bonvini RF, Werner KD, Buettner HJ, Buergelin KH, Zeller T. Retrieval of lost coronary guidewires during challenging percutaneous coronary interventions. *Cardiovasc Revasc Med.* 2010 Oct-Dec;11(4):262.e7-10.
142. Fontana P, Bonvini RF, Roffi M, Boehlen F, Reber G, de Moerloose P, Reny JL. *Rev Med Suisse.* 2010 Feb 10;6(235):302-5. [Evaluating the biological efficacy of clopidogrel: genotype or phenotype?]. *Rev Med Suisse.* 2010 Feb 10;6(235):302-5.
143. Bonvini RF, Sztajzel R, Dorsaz PA, Righini M, Bonvin C, Alibegovic J, Sigwart U, Camenzind E, Verin V, Sztajzel J. Incidence of atrial fibrillation after percutaneous closure of patent foramen ovale and small atrial septal defects in patients presenting with cryptogenic stroke. *Int J Stroke.* 2010 Feb;5(1):4-9.
144. Schütz N, Doll S, Bonvini RF. Erroneous placement of central venous catheter in the subclavian artery: retrieval and successful hemostasis with a femoral closure device. *Catheter Cardiovasc Interv.* 2011 Jan 1;77(1):154.
145. Noble S, Ibrahim R, Basmadjian A, Müller H, Lerch R, Roffi M. [Paravalvular leak following surgical valve replacement: is there a role for percutaneous paravalvular leak reduction?]. *Rev Med Suisse.* 2010 Jun 2;6(251):1154-8.
146. Berry C, Noble S, Ibrahim R, Grégoire J, Levesque S, L'allier PL, Tardif JC. Remodeling is a more important determinant of lumen size than atheroma burden in left main coronary artery disease. *Am Heart J.* 2010 Jul;160(1):188-194.e1.
147. Arzamendi D, Bilodeau L, Ibrahim R, Noble S, Gallo R, Lavoie-L'allier P, Gosselin G, Deguise P, Ly H, Tanguay JF, Doucet S. Role of rheolytic thrombectomy in massive pulmonary embolism with contraindication to systemic thrombolytic therapy. *EuroIntervention.* 2010 Jan;5(6):716-21.

148. Noble S, Sunthorn H, Prat-González S. [Apical aneurysm in a full-contact fighter]. *Rev Esp Cardiol*. 2011 Jun;64(6):535-6.
149. Frangos C, Noble S, Piazza N, Asgar A, Fortier A, Ly QH, Bonan R. Impact of bifurcation lesions on angiographic characteristics and procedural success in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. *Arch Cardiovasc Dis*. 2011 Apr;104(4):234-41.
150. Noble S, Ibrahim R. Embolization of an amplatzer mVSD occluder device used for percutaneous closure of an ascending aortic pseudoaneurysm: Case report and literature review. *Catheter Cardiovasc Interv*. 2011 Apr 26. doi: 10.1002/ccd.23094.
151. Frangos Noble C, De Benedetti E, Noble S. [Transradial approach for coronary angiography and angioplasty: the gold standard]. *Rev Med Suisse*. 2011 Mar 9;7(285):528-32.
152. Mahjoub H, Noble S, Ibrahim R, Potvin J, O'Meara E, Dore A, Marcotte F, Crépeau J, Bonan R, Mansour A, Bouchard D, Ducharme A, Basmadjian AJ. Description and assessment of a common reference method for fluoroscopic and transesophageal echocardiographic localization and guidance of mitral periprosthetic transcatheter leak reduction. *JACC Cardiovasc Interv*. 2011 Jan;4(1):107-14.
153. Meyer P, Gayda M, Normandin E, Guiraud T, Juneau M, Nigam A. "High-intensity interval training may reduce in-stent restenosis following percutaneous coronary intervention with stent implantation: A randomized controlled trial evaluating the relationship to endothelial function and inflammation." *Am Heart J* 2009;158:734-41. *Am Heart J*. 2010 Mar;159(3):e21.
154. Meyer P, Guiraud T, Curnier D, Juneau M, Gayda M, Nozza A, Nigam A. Exposure to extreme cold lowers the ischemic threshold in coronary artery disease patients. *Can J Cardiol*. 2010 Feb;26(2):e50-3.
155. Meyer P, Filippatos GS, Ahmed MI, Iskandrian AE, Bittner V, Perry GJ, White M, Aban IB, Mujib M, Dell'Italia LJ, Ahmed A. Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. *Circulation*. 2010 Jan 19;121(2):252-8.
156. Guiraud T, Juneau M, Nigam A, Gayda M, Meyer P, Mekary S, Paillard F, Bosquet L. Optimization of high intensity interval exercise in coronary heart disease. *Eur J Appl Physiol*. 2010 Mar;108(4):733-40.
157. Meyer P, Guiraud T, Gayda M, Juneau M, Bosquet L, Nigam A. High-intensity aerobic interval training in a patient with stable angina pectoris. *Am J Phys Med Rehabil*. 2010 Jan;89(1):83-6.
158. Sultan A, Steven D, Rostock T, Hoffmann B, Müllerleile K, Servatius H, Drewitz I, Lüker J, Meyer P, Salukhe T, Willems S. Intravenous Administration of Magnesium and Potassium Solution Lowers Energy Levels and Increases Success Rates Electrically Cardioverting Atrial Fibrillation. *J Cardiovasc Electrophysiol*. 2011 Aug 4. doi: 10.1111/j.1540-8167.2011.02146.x.
159. Yarol N, Tozzi P, von Segesser L, Kalangos A, Vogt P, Yerly P, Mach F, Pascual M, Meyer P, Hullin R. Selection and preoperative follow-up of heart transplantation

- candidates in the French part of Switzerland]. *Rev Med Suisse*. 2011 Jun 1;7(297):1212-6.
160. Desai RV, Guichard JL, Mujib M, Ahmed MI, Feller MA, Fonarow GC, Meyer P, Iskandrian AE, Bogaard HJ, White M, Aban IB, Aronow WS, Deedwania P, Waagstein F, Ahmed A. Reduced right ventricular ejection fraction and increased mortality in chronic systolic heart failure patients receiving beta-blockers: Insights from the BEST trial. *Int J Cardiol*. 2011 Jun 23.
 161. Meyer P, Desai RV, Mujib M, Feller MA, Adamopoulos C, Banach M, Lainscak M, Aban I, White M, Aronow WS, Deedwania P, Iskandrian AE, Ahmed A. Right ventricular ejection fraction <20% is an independent predictor of mortality but not of hospitalization in older systolic heart failure patients. *Int J Cardiol*. 2011
 162. Desai RV, Meyer P, Ahmed MI, Mujib M, Adamopoulos C, White M, Aban IB, Iskandrian AE, Ahmed A. Relationship between left and right ventricular ejection fractions in chronic advanced systolic heart failure: insights from the BEST trial. *Eur J Heart Fail*. 2011 Apr;13(4):392-7.
 163. Adamopoulos C, Meyer P, Desai RV, Karatzidou K, Ovalle F, White M, Aban I, Love TE, Deedwania P, Anker SD, Ahmed A. Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. *Eur J Heart Fail*. 2011 Feb;13(2):200-6.
 164. Bernier M, Marelli AJ, Pilote L, Bouchardy J, Bottega N, Martucci G, Therrien J. Atrial arrhythmias in adult patients with right- versus left-sided congenital heart disease anomalies. *Am J Cardiol*. 2010 Aug 15;106(4):547-51.
 165. Monney P, Stalder N, Clair M, Vogt P, Schwitter J, Meijboom EJ, Bouchardy J. [Cardiac MRI in the follow-up of adult congenital cardiomyopathy patients]. *Rev Med Suisse*. 2011 Jun 1;7(297):1194-9.
 166. Viallon M, Altrichter S, Pereira VM, Nguyen D, Sekoranja L, Federspiel A, Kulcsar Z, Sztajzel R, Ouared R, Bonvin C, Pfeuffer J, Lövblad KO. Combined use of pulsed arterial spin-labeling and susceptibility-weighted imaging in stroke at 3T. *Eur Neurol*. 2010;64(5):286-96.
 167. Bonvin C, Momjian-Mayor I, Sekoranja L, Lövblad KO, Altrichter S, Yilmaz H, Pereira VM, Loulidi J, Comelli M, Burkhard PR, Sztajzel RF. Stroke severity and residual flow determined by transcranial colour-coded ultrasound (TCCD) predict recanalization and clinical outcome during thrombolysis. *J Neurol Sci*. 2010 Sep 15;296(1-2):96-100.
 168. Fluri F, Hatz F, Rutgers MP, Georgiadis D, Sekoranja L, Schwegler G, Sarikaya H, Weder B, Müller F, Lüthy R, Arnold M, Reichhart M, Mattle HP, Tettenborn B, Nedeltchev K, Hungerbühler HJ, Sztajzel R, Baumgartner RW, Michel P, Lyrer PA, Engelter ST. Intravenous thrombolysis in patients with stroke attributable to small artery occlusion. *Eur J Neurol*. 2010 Aug;17(8):1054-60.
 169. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD,

- Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011 Sep 8;365(10):883-91.
170. Sarikaya H, Arnold M, Engelter ST, Lyrer PA, Michel P, Odier C, Weder B, Tettenborn B, Mueller F, Sekoranja L, Sztajzel R, Ballinari P, Mattle HP, Baumgartner RW. Intravenous thrombolysis in nonagenarians with ischemic stroke. *Stroke*. 2011 Jul;42(7):1967-70.
 171. Carballo D, Auer R, Carballo S, Windecker S, Matter C, Luscher T, Vogt P, Perneger T, Mach F, Rodondi N, Keller PF; SPUM-ACS. [A Swiss multicentric project to improve the prevention of cardiovascular event recurrence after acute coronary syndromes]. *Rev Med Suisse*. 2010 Mar 10;6(239):518, 520-2, 524.
 172. Darioli V, Carballo D, Carballo S. *Rev Med Suisse*. 2010 Oct 20;6(267):1957-60, 1962. [Customized management of pericarditis].
 173. Gauvreau GM, Pageau R, Séguin R, Carballo D, Gauthier J, D'Anjou H, Campbell H, Watson R, Mistry M, Parry-Billings M, Killian K, Renzi PM. Dose-response effects of TPI ASM8 in asthmatics after allergen. *Allergy*. 2011 Sep;66(9):1242-8.
 174. Pfenniger A, Wohlwend A, Kwak BR. Mutations in connexin genes and disease. *Eur J Clin Invest*. 2011 Jan;41(1):103-16.
 175. Scheckenbach KE, Crespín S, Kwak BR, Chanson M. Connexin channel-dependent signaling pathways in inflammation. *J Vasc Res*. 2011;48(2):91-103.
 176. Morel S, Kwak BR. Roles of Connexins in Atherosclerosis and Ischemia-Reperfusion Injury. *Curr Pharm Biotechnol*. In press 2011.
 177. Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, Hofer I, Jukema JW, Krams R, Kwak BR, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys PW, Waltenberger J, Weber C, Tokgözoğlu L. Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. *Thromb Haemost*. 2011 Jul 4;106(1):1-19.
 178. Angelillo-Scherrer A, Fontana P, Burnier L, Roth I, Sugamele R, Brisset A, Morel S, Nalli S, Sutter E, Chassot A, Capron C, Borgel D, Saller F, Chanson M, Kwak BR. Connexin 37 limits thrombus propensity by downregulating platelet reactivity. *Circulation*. 2011 Aug 23;124(8):930-9.
 179. Morel S, Burnier L, Roatti A, Chassot A, Roth I, Sutter E, Galan K, Pfenniger A, Chanson M, Kwak BR. Unexpected role for the human Cx37 C1019T polymorphism in tumour cell proliferation. *Carcinogenesis*. 2010 Nov;31(11):1922-31.
 180. Pfenniger A, Derouette JP, Verma V, Lin X, Foglia B, Coombs W, Roth I, Satta N, Dunoyer-Geindre S, Sorgen P, Taffet S, Kwak BR, Delmar M. Gap junction protein Cx37 interacts with endothelial nitric oxide synthase in endothelial cells. *Arterioscler Thromb Vasc Biol*. 2010 Apr;30(4):827-34.
 181. Chadjichristos CE, Scheckenbach KE, van Veen TA, Richani Saredine MZ, de Wit C, Yang Z, Roth I, Bacchetta M, Viswambharan H, Foglia B, Dudez T, van Kempen

- MJ, Coenjaerts FE, Miquerol L, Deutsch U, Jongasma HJ, Chanson M, Kwak BR. Endothelial-specific deletion of connexin40 promotes atherosclerosis by increasing CD73-dependent leukocyte adhesion. *Circulation*. 2010 Jan 5;121(1):123-31.
182. Asrih M, Pellioux C, Papageorgiou I, Lerch R, Montessuit C. Role of ERK1/2 activation in microtubule stabilization and glucose transport in cardiomyocytes. *Am J Physiol Endocrinol Metab*. In press 2011.
183. Tuma RF, Steffens S. Targeting the Endocannabinoid System to Limit Myocardial and Cerebral Ischemic and Reperfusion Injury. *Curr Pharm Biotechnol*. In press 2011.
184. Thomas A, Lenglet S, Chaurand P, Deglon J, Mangin P, Mach F, Steffens S, Wolfender JL, Staub C. Mass spectrometry for the evaluation of cardiovascular diseases based on proteomics and lipidomics. *Thromb Haemost*. 2011 Jul 4;106(1):20-33.
185. Thomas A, Déglon J, Lenglet S, Mach F, Mangin P, Wolfender JL, Steffens S, Staub C. High-throughput phospholipidic fingerprinting by online desorption of dried spots and quadrupole-linear ion trap mass spectrometry: evaluation of atherosclerosis biomarkers in mouse plasma. *Anal Chem*. 2010 Aug 1;82(15):6687-94.
186. Maggio AB, Farpour-Lambert NJ, Montecucco F, Pelli G, Marchand LM, Schwitzgebel V, Mach F, Aggoun Y, Beghetti M. Elevated E-selectin and diastolic blood pressure in diabetic children. *Eur J Clin Invest*. In press 2011.
187. Montecucco F, Braunersreuther V, Lenglet S, Delattre BMA, Pelli G, Buatois V, Guilhot F, Galan K, Vuilleumier N, Ferlin W, Fischer N, Vallée JP, Kosco-Vilbois M, Mach F. CC chemokine CCL5 plays a central role impacting infarct size and post-infarction heart failure in mice. *Eur Heart J*. In press 2011.
188. Frossard JL, Lenglet S, Montecucco F, Steffens S, Galan K, Pelli G, Spahr L, Mach F, Hadengue A. Role of CCL-2, CCR-2 and CCR-4 in cerulein-induced acute pancreatitis and pancreatitis-associated lung injury. *J Clin Pathol*. 2011;64:387-393
189. Montecucco F, Bertolotto M, Vuilleumier N, Franciosi U, Puddu A, Minetti S, Delrio A, Quercioli A, Bergamini E, Ottonello L, Pende A, Lenglet S, Pelli G, Mach F, Dallegri F, Viviani G. Acipimox reduces circulating levels of insulin and associated neutrophilic inflammation in metabolic syndrome. *Am J Physiol Endocrinol Metab*. In press 2011.
190. Montecucco F, Vuilleumier N, Pagano S, Lenglet S, Bertolotto M, Braunersreuther V, Pelli G, Kovari E, Pane B, Spinella G, Pende A, Palombo D, Dallegri F, Mach F, Roux-Lombard P. Anti-ApoA-1 auto-antibodies are active mediators of atherosclerotic plaque vulnerability. *Eur Heart J*. 2011;32:412-421.
191. Roux-Lombard P, Pagano S, Montecucco F, Satta N, Vuilleumier N. Auto-antibodies as Emergent Prognostic Markers and Possible Mediators of Ischemic Cardiovascular Diseases. *Clin Rev Allergy Immunol*. In press 2011.
192. Montecucco F, Quercioli A, Mirabelli-Badenier M, Viviani GL, Mach F. Statins in the treatment of acute ischemic stroke. *Curr Pharm Biotechnol*. In Press 2011.

193. Mirabelli-Badenier M, Braunersreuther V, Viviani GL, Dallegri F, Quercioli A, Veneselli E, Mach F, Montecucco F. CC and CXC chemokines are pivotal mediators of cerebral injury in ischemic stroke, *Thromb Haemost.* 2011;105:409-420.
194. Montecucco F, Pende A, Quercioli A, Mach F. Inflammation in the pathophysiology of essential hypertension. *J Nephrol.* 2011;24:23-34.
195. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. *World J Gastroenterol.* In Press 2011.
196. Montecucco F, Mach F. Update on inflammatory processes governing atherosclerotic plaque vulnerability and reperfusion injury. *Curr Pharm Biotechnol* In Press 2010.
197. Montecucco F, Noble S, Mach F. Inflammatory biomarkers. Handbook entitled "Inflammation and atherosclerosis" Springer. In press 2011.
198. Vuilleumier N, Pagano S, Bas S, Montecucco F, Guerne PA, Finckh A, Lovis C, Mach F, Hochstrasser D, Poux-Lombard P, Gabay C. Anti-Apolipoprotein A-1 IgG predict major cardiovascular events in patients with rheumatoid arthritis. *Arthritis Rheum.* 2010;62:2640-50.
199. Montecucco F, Lenglet S, Braunersreuther V, Pelli G, Pellioux C, Montessuit C, Lerch R, Deruaz M, Proudfoot AE, Mach F. Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice. *Arterioscler Thromb Vasc Biol.* 2010;30:1371-7.
200. Montecucco F, Lenglet S, Gayet-Ageron A, Bertolotto M, Pelli G; Palombo D, Pane B, Spinella G, Steffens S, Raffaghello L, Pistoia V, Ottonello L, Pende A, Dallegri F, Mach F. Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke. *Stroke.* 2010;41:1394-1404.
201. Montecucco F, Quercioli A, Dallegri F, Viviani GL, Mach F. New evidence for nicotinic acid treatment to reduce atherosclerosis. *Expert Rev Cardiovasc Ther.* 2010;8:1457-1467.
202. Quercioli A, Mach F, Montecucco F. Inflammation accelerates atherosclerotic processes in obstructive sleep apnea syndrome (OSAS). *Sleep Breath.* 2010;14:261-269.
203. Quercioli A, Montecucco F, Bertolotto M, Ottonello L, Pende A, Mach F, Dallegri F. Coronary artery calcification and cardiovascular risk: the role of RANKL/OPG signalling. *Eur J Clin Invest.* 2010;40:645-654.
204. Quercioli A, Mach F, Montecucco F. Novel Treatment Strategy with direct renin inhibition against heart failure. *Panminerva Med.* 2010;52:41-51.
205. Quercioli A, Viviani GL, Dallegri F, Mach F, Montecucco F. RANKL/OPG pathway is a promising target to reduce atherosclerotic plaque calcification. *Crit Pathw Cardiol.* 2010 9:227-230.
206. Montecucco F, Quercioli A, Mach F. Role of neutrophils in acute myocardial infarction. Handbook entitled "Neutrophils: Lifespan, Functions and Role in diseases." Nova Science Publishers, 2010, Chapter 13:351-360.

207. Fox ER, Young JH, Li Y, Dreisbach AW, Keating BJ, Musani SK, Liu K, Morrison AC, Ganesh S, Kutlar A, Ramachandran VS, Polak JF, Fabsitz RR, Dries DL, Farlow DN, Redline S, Adeyemo A, Hirschorn JN, Sun YV, Wyatt SB, Penman AD, Palmas W, Rotter JI, Townsend RR, Doumatey AP, Tayo BO, Mosley TH Jr, Lyon HN, Kang SJ, Rotimi CN, Cooper RS, Franceschini N, Curb JD, Martin LW, Eaton CB, Kardia SL, Taylor HA, Caulfield MJ, Ehret GB, Johnson T; International Consortium for Blood Pressure Genome-wide Association Studies (ICBP-GWAS), Chakravarti A, Zhu X, Levy D, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DI, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, Pihur V, Vollenweider P, O'Reilly PF, Amin N, Bragg-Gresham JL, Teumer A, Glazer NL, Launer L, Zhao JH, Aulchenko Y, Heath S, Söber S, Parsa A, Luan J, Arora P, Dehghan A, Zhang F, Lucas G, Hicks AA, Jackson AU, Peden JF, Tanaka T, Wild SH, Rudan I, Igl W, Milanesechi Y, Parker AN, Fava C, Chambers JC, Kumari M, Go MJ, van der Harst P, Kao WH, Sjögren M, Vinay DG, Alexander M, Tabara Y, Shaw-Hawkins S, Whincup PH, Liu Y, Shi G, Kuusisto J, Seielstad M, Sim X, Nguyen KD, Lehtimäki T, Matullo G, Wu Y, Gaunt TR, Onland-Moret NC, Cooper MN, Platou CG, Org E, Hardy R, Dahgam S, Palmen J, Vitart V, Braund PS, Kuznetsova T, Uiterwaal CS, Campbell H, Ludwig B, Tomaszewski M, Tzoulaki I, Palmer ND; CARDIoGRAM consortium; CKDGen consortium; KidneyGen consortium; EchoGen consortium; CHARGE-HF consortium, Aspelund T, Garcia M, Chang YP, O'Connell JR, Steinle NI, Grobbee DE, Arking DE, Hernandez D, Najjar S, McArdle WL, Hadley D, Brown MJ, Connell JM, Hingorani AD, Day IN, Lawlor DA, Beilby JP, Lawrence RW, Clarke R, Collins R, Hopewell JC, Ongen H, Bis JC, Kähönen M, Viikari J, Adair LS, Lee NR, Chen MH, Olden M, Pattaro C, Hoffman Bolton JA, Köttgen A, Bergmann S, Mooser V, Chaturvedi N, Frayling TM, Islam M, Jafar TH, Erdmann J, Kulkarni SR, Bornstein SR, Grässler J, Groop L, Voight BF, Kettunen J, Howard P, Taylor A, Guarrera S, Ricceri F, Emilsson V, Plump A, Barroso I, Khaw KT, Weder AB, Hunt SC, Bergman RN, Collins FS, Bonnycastle LL, Scott LJ, Stringham HM, Peltonen L, Perola M, Vartiainen E, Brand SM, Staessen JA, Wang TJ, Burton PR, Artigas MS, Dong Y, Snieder H, Wang X, Zhu H, Lohman KK, Rudock ME, Heckbert SR, Smith NL, Wiggins KL, Shriner D, Veldre G, Viigimaa M, Kinra S, Prabhakaran D, Tripathy V, Langefeld CD, Rosengren A, Thelle DS, Corsi AM, Singleton A, Forrester T, Hilton G, McKenzie CA, Salako T, Iwai N, Kita Y, Ogiwara T, Ohkubo T, Okamura T, Ueshima H, Umemura S, Eyheramendy S, Meitinger T, Wichmann HE, Cho YS, Kim HL, Lee JY, Scott J, Sehmi JS, Zhang W, Hedblad B, Nilsson P, Smith GD, Wong A, Narisu N, Stancáková A, Raffel LJ, Yao J, Kathiresan S, O'Donnell C, Schwartz SM, Ikram MA, Longstreth WT Jr, Seshadri S, Shrine NR, Wain LV, Morken MA, Swift AJ, Laitinen J, Prokopenko I, Zitting P, Cooper JA, Humphries SE, Danesh J, Rasheed A, Goel A, Hamsten A, Watkins H, Bakker SJ, van Gilst WH, Janipalli C, Mani KR, Yajnik CS, Hofman A, Mattace-Raso FU, Oostra BA, Demirkan A, Isaacs A, Rivadeneira F, Lakatta EG, Orru M, Scuteri A, Ala-Korpela M, Kangas AJ, Lyytikäinen LP, Soininen P, Tukiainen T, Würz P, Ong RT, Dörr M, Kroemer HK, Völker U, Völzke H, Galan P, Hercberg S, Lathrop M, Zelenika D, Deloukas P, Mangino M, Spector TD, Zhai G, Meschia JF, Nalls MA, Sharma P, Terzic J, Kumar MJ, Denniff M, Zukowska-Szczepowska E, Wagenknecht LE, Fowkes FG, Charchar FJ, Schwarz PE, Hayward C, Guo X, Bots ML, Brand E, Samani N, Polasek O, Talmud PJ, Nyberg F, Kuh D, Laan M, Hveem K, Palmer LJ, van der Schouw YT, Casas JP, Mohlke KL, Vineis P, Raitakari O,

- Wong TY, Tai ES, Laakso M, Rao DC, Harris TB, Morris RW, Dominiczak AF, Kivimaki M, Marmot MG, Miki T, Saleheen D, Chandak GR, Coresh J, Navis G, Salomaa V, Han BG, Kooner JS, Melander O, Ridker PM, Bandinelli S, Gyllenstein UB, Wright AF, Wilson JF, Ferrucci L, Farrall M, Tuomilehto J, Pramstaller PP, Elosua R, Soranzo N, Sijbrands EJ, Altshuler D, Loos RJ, Shuldiner AR, Gieger C, Meneton P, Uitterlinden AG, Wareham NJ, Gudnason V, Rettig R, Uda M, Strachan DP, Witteman JC, Hartikainen AL, Beckmann JS, Boerwinkle E, Boehnke M, Larson MG, Jarvelin MR, Psaty BM, Abecasis GR, Elliott P, van Duijn CM, Newton-Cheh C. Association of genetic variation with systolic and diastolic blood pressure among African Americans: the Candidate Gene Association Resource study. *Hum Mol Genet.* 2011 Jun 1;20(11):2273-84.
208. Johnson AD, Newton-Cheh C, Chasman DI, Ehret GB, Johnson T, Rose L, Rice K, Verwoert GC, Launer LJ, Gudnason V, Larson MG, Chakravarti A, Psaty BM, Caulfield M, van Duijn CM, Ridker PM, Munroe PB, Levy D; Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium; Global BPgen Consortium; Women's Genome Health Study. Association of hypertension drug target genes with blood pressure and hypertension in 86,588 individuals. *Hypertension.* 2011 May;57(5):903-10.
209. Ehret GB, Pechère-Bertschi A. [Resistant hypertension]. *Rev Med Suisse.* 2010 Sep 15;6(262):1721-2, 1724-7.
210. Meyer TE, Verwoert GC, Hwang SJ, Glazer NL, Smith AV, van Rooij FJ, Ehret GB, Boerwinkle E, Felix JF, Leak TS, Harris TB, Yang Q, Dehghan A, Aspelund T, Katz R, Homuth G, Kocher T, Rettig R, Ried JS, Gieger C, Prucha H, Pfeufer A, Meitinger T, Coresh J, Hofman A, Sarnak MJ, Chen YD, Uitterlinden AG, Chakravarti A, Psaty BM, van Duijn CM, Kao WH, Witteman JC, Gudnason V, Siscovick DS, Fox CS, Köttgen A; Genetic Factors for Osteoporosis Consortium; Meta Analysis of Glucose and Insulin Related Traits Consortium. Genome-wide association studies of serum magnesium, potassium, and sodium concentrations identify six Loci influencing serum magnesium levels. *PLoS Genet.* 2010 Aug 5;6(8). pii: e1001045.
211. Ehret GB. Genome-wide association studies: contribution of genomics to understanding blood pressure and essential hypertension. *Curr Hypertens Rep.* 2010 Feb;12(1):17-25.
212. Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, Sinner MF, de Bakker PI, Mueller M, Lubitz SA, Fox E, Darbar D, Smith NL, Smith JD, Schnabel RB, Soliman EZ, Rice KM, Van Wagoner DR, Beckmann BM, van Noord C, Wang K, Ehret GB, Rotter JI, Hazen SL, Steinbeck G, Smith AV, Launer LJ, Harris TB, Makino S, Nelis M, Milan DJ, Perz S, Esko T, Köttgen A, Moebus S, Newton-Cheh C, Li M, Möhlenkamp S, Wang TJ, Kao WH, Vasan RS, Nöthen MM, MacRae CA, Stricker BH, Hofman A, Uitterlinden AG, Levy D, Boerwinkle E, Metspalu A, Topol EJ, Chakravarti A, Gudnason V, Psaty BM, Roden DM, Meitinger T, Wichmann HE, Witteman JC, Barnard J, Arking DE, Benjamin EJ, Heckbert SR, Kääh S. Common variants in *KCNN3* are associated with lone atrial fibrillation. *Nat Genet.* 2010 Mar;42(3):240-4.
213. Pfeufer A, van Noord C, Marcianti KD, Arking DE, Larson MG, Smith AV, Tarasov KV, Müller M, Sotoodehnia N, Sinner MF, Verwoert GC, Li M, Kao WH,

Köttgen A, Coresh J, Bis JC, Psaty BM, Rice K, Rotter JI, Rivadeneira F, Hofman A, Kors JA, Stricker BH, Uitterlinden AG, van Duijn CM, Beckmann BM, Sauter W, Gieger C, Lubitz SA, Newton-Cheh C, Wang TJ, Magnani JW, Schnabel RB, Chung MK, Barnard J, Smith JD, Van Wagoner DR, Vasani RS, Aspelund T, Eiriksdottir G, Harris TB, Launer LJ, Najjar SS, Lakatta E, Schlessinger D, Uda M, Abecasis GR, Müller-Miyahara B, Ehret GB, Boerwinkle E, Chakravarti A, Soliman EZ, Lunetta KL, Perz S, Wichmann HE, Meitinger T, Levy D, Gudnason V, Ellinor PT, Sanna S, Kääb S, Witteman JC, Alonso A, Benjamin EJ, Heckbert SR. Genome-wide association study of PR interval. *Nat Genet.* 2010 Feb;42(2):153-9.

214. North KE, Franceschini N, Avery CL, Baird L, Graff M, Leppert M, Chung JH, Zhang J, Hanis C, Boerwinkle E, Volcik KA, Grove ML, Mosley TH, Gu C, Heiss G, Pankow JS, Couper DJ, Ballantyne CM, Linda Kao WH, Weder AB, Cooper RS, Ehret GB, O'Connor AA, Chakravarti A, Hunt SC. Variation in the checkpoint kinase 2 gene is associated with type 2 diabetes in multiple populations. *Acta Diabetol.* 2010 Dec;47(Suppl 1):199-207.